RA Session II, Taysha
December 18, 2020 10:19 AM EST
Startups
Manufacturing

Taysha Gene Ther­a­pies looks to build on rapid IPO with $85M dev-man­u­fac­tur­ing plant in North Car­oli­na

Conner Mitchell

Taysha Gene Ther­a­pies went pub­lic with a bang ear­li­er this year with a $157 mil­lion IPO just five months af­ter its Se­ries A fi­nanc­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In­tel­lia touts first clin­i­cal out­comes on CRISPR-based AT­TR amy­loi­do­sis as­set

Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Ex­clu­sive: Athena Coun­tou­ri­o­tis' Aven­zo taps Shang­hai biotech for ADC, adds new funds

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times